PTC Therapeutics, Inc.

How big is PTC Therapeutics, Inc.?

As of Jun 18, PTC Therapeutics, Inc. has a market capitalization of $4.03 billion, with net sales of $1.77 billion and a net profit of $594.84 million over the latest four quarters. The company reported shareholder's funds of -$1.10 billion and total assets of $1.72 billion as of Dec 24.

Market Cap: As of Jun 18, PTC Therapeutics, Inc. has a market capitalization of 4,030.22 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, PTC Therapeutics, Inc. reported net sales of 1,772.76 million and a net profit of 594.84 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -1,098.07 million and total assets of 1,716.76 million.

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for rare disorders, with recent net sales of $1.176 billion and a market cap of $4.03 billion. The company has a P/E ratio of 6.00 and no dividend yield.

Overview: <BR>PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company focused on the discovery, development, and commercialization of clinically-differentiated medicines for patients with rare disorders, operating in the Pharmaceuticals & Biotechnology industry within the small-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,176 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 867 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4,030.22 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 6.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 9.29 <BR>Return on Equity: -400.08% <BR>Price to Book: -21.70 <BR><BR>Contact Details: <BR>Address: 100 Corporate Ct, SOUTH PLAINFIELD NJ: 07080-2400 <BR>Tel: 1 908 2227000 <BR>Website: https://www.ptcbio.com/

Should I buy, sell or hold PTC Therapeutics, Inc.?

Who are in the management team of PTC Therapeutics, Inc.?

As of March 2022, the management team of PTC Therapeutics, Inc. includes CEO Dr. Stuart Peltz and Independent Chairman Mr. Michael Schmertzler, along with several independent directors: Dr. Allan Jacobson, Ms. Stephanie Okey, Ms. Emma Reeve, Mr. David Southwell, and Dr. Glenn Steele. This team provides governance and strategic direction for the company.

As of March 2022, the management team of PTC Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Michael Schmertzler, Independent Chairman of the Board<BR>- Dr. Stuart Peltz, Chief Executive Officer and Director<BR>- Dr. Allan Jacobson, Independent Director<BR>- Ms. Stephanie Okey, Independent Director<BR>- Ms. Emma Reeve, Independent Director<BR>- Mr. David Southwell, Independent Director<BR>- Dr. Glenn Steele, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is PTC Therapeutics, Inc. technically bullish or bearish?

As of September 2, 2025, PTC Therapeutics, Inc. shows a bullish trend supported by strong indicators like MACD and Bollinger Bands, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with a 1-month return of 26.27% and a 1-year return of 77.23%.

As of 2 September 2025, the technical trend for PTC Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate bullishness across both periods. Daily moving averages confirm a bullish trend as well. However, the weekly RSI is bearish, which suggests some caution. Dow Theory and OBV are both mildly bullish on a weekly and monthly basis. <BR><BR>In terms of performance, PTC Therapeutics has significantly outperformed the S&P 500 across multiple periods, with a 1-month return of 26.27% compared to the S&P 500's 2.33%, and a 1-year return of 77.23% versus 17.14%.